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with baseline population characteristics may potentially con-
found these ﬁndings.
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Sikirica V1, Doshi D2, Feliu A3, Schein JR1, Boccuzzi SJ4, Janagap C1,
Shim B3
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA,
2Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, San Diego, CA, USA,
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OBJECTIVES: To examine treatment failure rates, disease-
related medical complications and health care costs among CAP
outpatients treated with levoﬂoxacin (LEVO) or amoxicillin/
clavulanate (AC). METHODS: Using adjudicated, commercial
health insurance claims data (PharMetrics, Inc.), patients with
an outpatient CAP diagnosis between July 2003 and December
2004, aged 18–64, with 6-months enrollment pre– and
post–diagnosis, receiving LEVO or AC monotherapy within 3
days of diagnosis, were identiﬁed. Patients with recent hospital-
ization (10 days), prior antibiotic therapy (30 days), or immuno-
compromised state were excluded. Treatment failure was deﬁned
as receipt of a renewal or alternative antibiotic claim, or hospi-
talization 28 days post–prescription claim. Complications and
infection related costs were tracked for 6-months post–
diagnosis. Demographic, clinical, pre–index utilization, and
study endpoints were evaluated via descriptive, univariate
(Wilcoxon and Chi-Square tests for continuous and dichotomous
variables, respectively) and multivariate techniques (logistic
regression for treatment failure and complications, General
Linear Model for costs). RESULTS: Of 4030 LEVO and 951 AC
patients analyzed, the cohorts had similar demographic and clin-
ical proﬁles (pre–diagnosis utilization and cost, comorbidity
burden, Charlson score), except age (LEVO vs AC: 45.8 vs. 42.7
y, p < 0.001), gender distribution (females 49.5% vs. 53.4%, p
< 0.001), and asthma prevalence (4.9% vs 6.8%, p = 0.017). The
AC group had a higher percentage (22.0% vs. 18.5%, p = 0.015)
and likelihood (OR = 1.27, 95% CI 1.07–1.52, p = 0.007) of
treatment failure than the LEVO group. The rates of infec-
tion–related complications were 8.6% for LEVO and 8.2% for
AC; (OR 1.12, 95% CI 0.80–1.56, p = 0.52). No difference was
observed in infection–related costs (mean ± SD: LEVO $1067 ±
3562 vs. AC $1159 ± 5874). CONCLUSION: LEVO and AC
groups were comparable. The LEVO group experienced signiﬁ-
cantly lower treatment failure, but no signiﬁcant differences in
complications or costs, compared to the AC group, in outpatient
CAP.
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OBJECTIVES: To examine treatment failure rates among com-
munity acquired pneumonia (CAP) patients treated with lev-
oﬂoxacin vs. macrolides (azithromycin, clarithromycin or
erythromycin) in an outpatient setting. METHODS: A post-hoc,
retrospective database analysis using eligibility (6-months pre
and post), medical and pharmacy claims from a large US com-
mercial health plan. Adults (≥18) with an outpatient primary
diagnosis of CAP between January 1, 2004 and March 31, 2005,
and treated within 3 days of diagnosis with oral levoﬂoxacin or
macrolides were included. Patients with a recent hospitalization
(10 days), prior antibiotic therapy (30 days), or immunocom-
promised state were excluded. Treatment failure was deﬁned as
receipt of receipt of renewal or alternative antibiotic claim, or
hospitalization for CAP within 30 days of initial therapy. Mul-
tivariate logistic regression compared treatment failure rates
between the two groups. Multivariate regression included all rel-
evant variables describing patient characteristics including age,
gender, region, Charlson comorbidity score, pre-existing respi-
ratory, cardiovascular disease and diabetes. An identical sub-
group analysis of patients ≥50 years old was conducted.
RESULTS: Of 7526 CAP patients included, 2968 (39.4%) were
treated with levoﬂoxacin and 4558 (60.6%) with a macrolide.
Levaquin patients were older (mean 48.7 vs. 43.7) and had a
more severe Charlson comorbidity status (mean 0.40 vs. 0.25).
Unadjusted treatment failure rates were 21.1% and 22.7% in
levoﬂoxacin and macrolide cohorts, respectively. After adjust-
ment, compared to macrolides, levoﬂoxacin patients were less
likely to fail treatment (OR = 0.84, 95% CI: 0.73, 0.94, P =
0.002). Of 2967 subjects ≥50 years old, 21.8% of levoﬂoxacin
and 25.4% of macrolide patients failed treatment, respectively;
likelihood of treatment failure was signiﬁcantly lower for lev-
oﬂoxacin patients (OR = 0.79, 95% CI: 0.66, 0.94, P = 0.007).
CONCLUSION: Compared with macrolides, Levoﬂoxacin was
associated with lower treatment failure rates in CAP patients
treated in an outpatient setting. This difference was greater in
patients ≥50 years old.
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OBJECTIVES: Vancomycin is often considered ﬁrst-line for com-
plicated gram+ infections; however, a rise in resistant infections
in both hospital and community settings may impact efﬁcacy and
total cost of treatment. Our objective was to systematically eval-
uate the clinical efﬁcacy and resource use/economic characteris-
tics of vancomycin in recent randomized clinical trials (RCT) or
economic studies for treatment of complicated gram+ infections,
such as skin and soft tissue infections (SSTI), including methi-
cillin-resistant staphylococcus aureus (MRSA). METHODS: A
literature search was conducted in PubMed, EMBASE, IPA, and
infectious disease abstract databases to identify clinical or eco-
nomic studies of vancomycin published from 2000–2006. Clin-
ical outcomes data were synthesized by study design, infection
type, MRSA status, intent to treat (ITT) efﬁcacy, microbiologic
cure, MRSA efﬁcacy, and adverse events (AEs). Efﬁcacy data
were pooled when possible. Economic data abstracted included
hospital length of stay (LOS), length of treatment (LOT), and
cost of treatment (COT) adjusted to 2006 US$. RESULTS:
Twelve studies (including 5 RCTs with 4 in SSTI) were identiﬁed
reporting speciﬁc clinical efﬁcacy outcomes and/or economic
data. The ITT average efﬁcacy (range) for vancomycin 1 gm IV
q12hr for SSTIs was 85% (76.9–88.5%) and microbiologic cure
was 89% (77–97.6%). For MRSA SSTIs, efﬁcacy was lower at
68% (50–81%). Incidence of drug-related AEs was 3.6–20.6%,
and drug-related discontinuations 4.5–5.8%. Hospital LOS
ranged from 8–15 days, and LOT 9–11 days. Resistance
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increased COT, with an MRSA SSTI incurring at least 2–3 more
days for LOS and total COT > $23,000. CONCLUSION: Van-
comycin’s clinical and economic efﬁciency may be reduced for
patients with complicated MRSA SSTIs. The level of antibiotic
resistance should be factored into comparative economic analy-
ses of vancomycin and new treatments for gram+ infections.
PIN6
INITIATION OF ANTIVIRAL THERAPY AMONG CHRONIC
HEPATITIS C PATIENTS ENROLLED IN MEDICAID
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OBJECTIVES: To identify factors contributing to the initiation
of antiviral therapy in patients with chronic Hepatitis C virus
(HCV) infection in a Medicaid population. METHODS: Florida
Medicaid claims from January 2000 to December 2004 were
analyzed for persons with a diagnosis of HCV infection (ICD 9
codes: 70.50, 70.54). Eligibility was deﬁned as continuous
enrollment for 12 months before and after the ﬁrst HCV claim
(index date). Treatment initiation was deﬁned as at least one
claim with an NDC code for ribavirin, interferon, peg-interferon
or interferon alfa-2b + ribavirin after the index date. Antiviral
treated cases and non-treated controls were matched 1 : 2 on
diagnosis year, age at diagnosis, and gender. Predictors of antivi-
ral treatment initiation, including patient characteristics, Charl-
son comorbidity score, other chronic diseases, and medical
services utilization in the 12 months before the index date were
examined using logistic regression. RESULTS: Of 10,016 HCV
patients, 2563 met eligibility criteria. Of these, 550 had more
than1 antiviral medication claim and 2013 had no antiviral
claims. Exclusion of 155 with medications prior to HCV index
date, 395 patients received treatment initiation. The rate of treat-
ment for newly diagnosis patients was 16.4% (395/ (2563–395))
to 21.5% (550/2563). Liver biopsy was associated with a 4-fold
increase in the likelihood of treatment initiation (OR = 3.9, p <
0.0001). Factors associated with a lower likelihood of treatment
initiation included were history of alcoholism (OR = 0.32, p <
0.001), Charlson comorbidity score of 3 and 4 (OR = 0.65, p =
0.027), and a history of hospitalization in the year before index
diagnosis (OR = 0.51, p < 0.001). CONCLUSION: Chronic
hepatitis C patients enrolled in Medicaid appear to be treated at
a lower rate than observed in other insured populations, with
sicker patients being less likely to receive antiviral therapy. Addi-
tional research is needed to identify barriers to treatment initia-
tion among this population.
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OBJECTIVES: To estimate the prevalence of cachexia diagnosis
and treatment among patients with HIV/AIDS. METHODS:
Using a large US managed care claims database (approximately
51 million covered lives; 75 plans), we identiﬁed all persons who
had ≥1 paid claim listing a primary or secondary diagnosis of
HIV/AIDS (ICD-9-CM 042) during calendar years 2004–2005.
A concomitant diagnosis of cachexia was assumed if the patient
also had ≥1 paid claim during this timeframe listing a primary
or secondary diagnosis of malnutrition (ICD-9-CM 263.xx),
cachexia (ICD-9-CM 799.4), or other related codes (i.e., ICD-9-
CM 783.0, 783.2x, or 783.3). Pharmacologic treatment of
cachexia in these patients was assumed if ≥1 pharmacy claim for
megestrol acetate, oxandrolone, somatropin, or dronabinol was
paid during the same timeframe. RESULTS: A total of 23,929
persons had ≥1 claim listing a diagnosis of HIV/AIDS during
2004–2005. Of these, 134 also had a cachexia diagnosis but no
treatment, 572 had cachexia treatment but no diagnosis code,
and 1028 had a diagnosis code and were treated. Overall preva-
lence of cachexia was therefore estimated at 1734 persons, or
72.5 per 1000 persons with HIV/AIDS. Higher cachexia preva-
lence was observed among persons aged 45+ years and men,
respectively. CONCLUSION: In this database, 7–8% of all
persons with HIV/AIDS were cachectic, based on diagnostic and
treatment evidence. Approximately 8% of prevalent cachexia
cases did not receive an indicated pharmacologic treatment. As
many as one-third of prevalent cases (i.e., 572 of 1734) cannot
be ascertained through the use of ICD-9-CM diagnosis codes
alone. This is not surprising, insofar as all patients in our sample
have a diagnosis of HIV/AIDS and US payers generally require
only one diagnosis code to effect claim payment. These ﬁndings
underscore the importance of considering use of pharmacologic
treatment in estimating prevalence of comorbid conditions in
persons with chronic diseases.
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BURDEN OF HERPES ZOSTER AND HEALTH AND BUDGET
IMPACT OF A VACCINATION PROGRAM
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OBJECTIVES: To estimate the disease burden of herpes zoster
(HZ) in people age 60+ and health and budget impact (HBI) of
a vaccine to prevent HZ from the payer’s perspective.
METHODS: The number of annual HZ cases and the associated
costs for the 60+ population were estimated from published inci-
dence, the base case U.S. population in 2006, and the age-
speciﬁc one year average incremental cost of HZ derived from a
U.S. claims database. A model was constructed to track individ-
uals through three states (living not vaccinated, living and vac-
cinated, deceased) from year 2006–2014. Vaccine usage rates
were assumed to be between 1–3% in 2006, 4–10% in 2007,
and 6–18% in years 2008–2014. Age speciﬁc efﬁcacy from the
Shingles Prevention Study was used to estimate HZ cases and
costs averted, as well as the net cost of a vaccination program
at a vaccine price of $150/dose. RESULTS: The annual incident
number of HZ cases was estimated at 428,000 (60+ population).
Annual direct medical costs were estimated at $494 million.
Approximately 30% to 60% of the 60+ population were vacci-
nated by year 2014. Through 2014, vaccination was projected
to avert between 210,000 and 540,000 incident cases of HZ,
resulting in cost avoidance between $190 and $460 million, and
a net cost of the vaccination program between 1.8 and 4.2
billion. The estimated lower and upper bounds of the average
per-member-per-month cost for years 2006–2014, for vaccinat-
ing a 60+ population with an age distribution (total population)
that is equivalent to that of the U.S. population were 6 and 13
cents respectively. CONCLUSION: HZ imposes a signiﬁcant
health and economic burden on the 60+ population. An HZ vac-
cination program is estimated to have a minimal budget impact
and may potentially reduce the disease burden of HZ.
